

# MSS 2024

HYBRID

## All-scale continuous mRNA-LNP manufacturing

*Flora Binder, Daniel Marquez Martin, Brice Pawelec, Jean de Seze, Christophe Bonneville  
Dillico, Meylan, France*

Industrial batch-wise mRNA production was implemented in the context of the pandemic, using manufacturing solutions already available and developed for conventional vaccines. This way to proceed goes with numerous drawbacks and does not take full advantage of the benefits of this new modality.

Dillico proposes to revolutionize the way mRNA pharmaceuticals are developed and manufactured with an innovative integrated and digitized solution. All-ScaleFlow™ technology, based on a continuous manufacturing approach, enables the production of formulated mRNAs, from very small quantities for pre-clinical phases to commercial scale, with the same equipment. During this talk we will present how All-ScaleFlow™ technology solves the substantial drawbacks of the currently implemented batch production mode and enables to remove the scale-up activity that has hitherto been extremely costly and time-consuming.

Experimental results show that this innovation leads to significant gains: superior quality of mRNA products (real-time control, confined processes, elimination of hold times, low shear stress), great flexibility in terms of capacity and a reduction of raw materials consumption through high yield.

 PORTOROZ, SLOVENIA

 3-7 June 2024